Navigation Links
Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
Date:9/21/2010

RYE, N.Y., Sept. 21 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Rodman & Renshaw Annual Global Investment Conference held September 12-15 in New York City.  The global investment conference attracted more than 5,000 investors and other attendees.  

"Curemark was one of only a handful of private companies invited to present at the conference, which included a full roster of 610 companies presenting," said Dr. Joan Fallon said, Curemark founder and CEO.  "To be able to participate was a terrific opportunity to showcase our progress, as the event was essentially a packed house."

At the conference, Fallon discussed the momentum of Curemark's drug pipeline.  CM-AT, the company's autism treatment in development, is currently in Phase III clinical trials at 13 sites nationwide and has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).  The FDA also has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of the company's compound CM-4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

Curemark's autism treatment targets enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- HealthMine surveys with 9,250 insured consumers fielded from February ... want help from their plans in five key areas: ... 2) help closing gaps in care, 3) better digital ... relevant, real-time guidance. Meeting these needs is essential to ... A Reason to Stay Engaged in Health ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the firm ... the firm, will concentrate her practice in elder law, Medicaid planning and applications, and ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at the ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate about ... what is often a very difficult and challenging time.” , A Certified Medical ...
Breaking Medicine News(10 mins):